LivingGLP1
Study S000797

A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0721-8060 in Healthy Adult Participants Living With Overweight or Obesity

ClinicalTrials.gov record

Registration

Registration
NCT07767175
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE1
Masking
DOUBLE
Status
RECRUITING
Enrollment
142
Start
2026-08-12
Primary completion
2027-09-23
Lead sponsor
Novo Nordisk A/S
Conditions
Overweight; Obesity
Interventions
DRUG:NNC0721-8060; DRUG:Semaglutide; DRUG:Placebo
Results posted
FALSE
Individual participant data sharing
YES
Secondary identifiers
OTHER:U1111-1334-3077

Registered primary outcomes

  • Part A: Number of treatment emergent adverse events (TEAE) [From Day 1 to Day 36]
  • Part B: Number of treatment emergent adverse events (TEAE) [From Day 1 to Day 57]
  • Part C: Change from baseline in body weight [From Day 1 to Day 85]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.